Skip to main content

Table 5 Value of further research on IVIG for severe sepsis/septic shock: ENBS and optimal sample size of a trial, according to model for the synthesis of effectiveness evidence (see Table 2 for detailed specification of the models)

From: Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial

Scenarios for alternative synthesis models of effectiveness evidence Maximum ENBS Optimal sample size per arm ( n* )
M1 £ 136,703,882 1900
M2 £ 687,441,146 1200
M3 £ 1,010,953,361 800
M4a £ 605,931,859 900
M4b £ 365,050,246 800
  1. The ENBS provides the societal payoff to the proposed research. It is computed as the difference between the value of sample information (EVSI) for a particular research design and the costs of sampling. IVIG, intravenous immunoglobulin; ENBS: expected net benefit of sampling.